-
Thematic Analysis
Rare Disease ​Pipeline Analysis ​Landscape, 2023
This report investigates the Rare Disease ​Pipeline Analysis ​Landscape in 2023 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize these trends within your sector.
-
Product Insights
Cutaneous Squamous Cell Carcinoma (cSCC) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Cutaneous Squamous Cell Carcinoma (cSCC) Clinical Trial Report Overview A total of 161 cSCC clinical trials were conducted as of February 2024. The cSCC clinical trial report provides a comprehensive understanding of the Cutaneous Squamous Cell Carcinoma clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       ...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Allergen For Allergic Rhinitis in Allergic Rhinitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Allergen For Allergic Rhinitis in Allergic Rhinitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Allergen For Allergic Rhinitis in Allergic Rhinitis Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – REGN-4336 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - REGN-4336 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. REGN-4336 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – REGN-5381 in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - REGN-5381 in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. REGN-5381 in Congestive Heart Failure (Heart Failure) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – REGN-5381 in Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - REGN-5381 in Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. REGN-5381 in Hypertension Drug Details: REGN5381 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nezastomig in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nezastomig in Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nezastomig in Renal Cell Carcinoma Drug Details: Nezastomig (REGN-5678) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – REGN-5093M114 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - REGN-5093M114 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. REGN-5093M114 in Non-Small Cell Lung Cancer Drug Details: REGN-5093M114 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGN-193408 SR in Open-Angle Glaucoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGN-193408 SR in Open-Angle Glaucoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGN-193408 SR in Open-Angle Glaucoma Drug Details: AGN-193408 SR is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) Drug Details:...